Key Highlights

  • Medifast (NYSE:MED) reported a third quarter adjusted loss of USD 0.19 per share on October 26, 2026, against a published consensus loss of USD 0.35, while the GAAP loss was USD 1.57 per share.
  • Revenue fell 19.4% to USD 72.0 million from USD 89.4 million, and active earning coaches dropped 47.7% to 10,200 from 19,500, with a further decline expected through year end.
  • Revenue per active earning coach rose 54.1% to USD 7,064, adjusted gross margin rose 220 basis points to 71.7%, and cash and investments were USD 172.5 million with no debt.
  • Guidance for the fourth quarter calls for revenue of USD 55 million to USD 75 million and income of USD 0.00 to USD 0.25 per share, with full year revenue of USD 280 million to USD 300 million.

What Medifast Reported

Medifast reported third quarter 2026 results on October 26, 2026. Revenue was USD 72.0 million, down 19.4%, and the GAAP loss was USD 1.57 per share against USD 0.21 a year earlier, reflecting restructuring charges. Excluding charges tied to its Catalyst restructuring program, the adjusted loss was USD 0.19 per share, a beat of about 46% against the published consensus loss of USD 0.35, simple arithmetic on two published numbers. Gross margin was 69.5%, flat year on year, and adjusted gross margin was 71.7%. Chief executive Nick Johnson said the company believes it is on track to deliver profitability in the fourth quarter and described the quarter as being about execution.

Coaches, GLP-1 Pressure and Guidance

Client acquisition pressure, including rapid adoption of GLP-1 weight loss medicines, is the central challenge, and the coach base shrank to 10,200 from 19,500. Remaining coaches are producing more, with revenue per coach up 54.1%, but total revenue still fell. Management expects the coach count to keep declining through the end of 2026. Fourth quarter revenue is guided to USD 55 million to USD 75 million, a wide range that brackets the third quarter's USD 72.0 million. Full year guidance is for a GAAP loss of USD 1.80 to USD 2.05 per share and a non-GAAP loss of USD 0.45 to USD 0.70, with adjusted EBITDA excluding interest income of USD 10 million to USD 14 million.

Balance Sheet, Risks and What to Watch

Published market data put the market value of Medifast (NYSE:MED) near USD 135.4 million, below the USD 172.5 million of cash, equivalents and investments, simple arithmetic on two published numbers, although cash can fall as restructuring and operating costs are paid. The company has no debt. The risks are further coach attrition, continued pressure from GLP-1 drugs, the execution of the Catalyst cost program and the width of the fourth quarter range. The release did not discuss a dividend. Investors can watch whether the fourth quarter delivers the promised profit, the coach count trend and how the revenue guidance compares with the third quarter's USD 72.0 million.

Where Things Stand

The adjusted beat reflects cost cuts and a better adjusted gross margin, not growth, because revenue fell 19.4% and the coach base fell 47.7%. Management guided to profitability in the fourth quarter, and cash of USD 172.5 million with no debt gives room to execute. For Medifast (NYSE:MED) the evidence is mixed: restructuring is lowering losses, but GLP-1 competition keeps pressuring sales, so the fourth quarter report will test whether the turnaround is real.